A PAT Solution for Automated Mill Control - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A PAT Solution for Automated Mill Control
The authors describe the implementation of an on-line particle-size analyzer on an active pharmaceutical ingredient milling operation at a commercial site.


Pharmaceutical Technology
Volume 34, Issue 1

Conclusions

The PAT initiative encourages the pharmaceutical industry to embrace new analytical approaches with the aim of transforming process development and manufacture. Realtime process monitoring and automated control are essential elements of this transformation, which has the potential to improve product quality, cut production costs and reduce time to market.

This case study highlights the availability, relevance, and benefits of a commercially available PAT solution for particle-size analysis. For pharmaceutical products, particle size is often a critical quality attribute that directly impacts performance and/or manufacturability, so better control delivers significant gains. An on-line system was used to transform a stand-alone manual mill into an automated process unit that will integrate into a manufacturing facility with a distributed control system or statistical process control. The Insitec analyzer used is a proven process solution for real-time particle sizing that additionally meets pharmaceutical industry requirements for clean in place, sterilize in place, validation and 21 CFR Part 11, the federal regulations providing guidelines on electronic records and electronic signatures in the United States.

The benefits of automating control include improved product quality, increased throughput, and less waste. Furthermore, automation opens up a route to semicontinuous operation and real-time release, important long-term goals in reaching operational excellence.

Qualification of an automated mill with closed-loop control delivers a solution that could potentially be used elsewhere in the company for both pilot- and full-scale operations. Semicontinuous operation with extended run times is a realistic and attractive alternative to conventional batch operations.

Alon Vaisman* is an application development manager at Malvern Instruments, Enigma Business Park, Grovewood Road, Malvern, Worcestershire, WR14 1XZ, UK, tel: +44 (0)1684 892456, fax +44 (0)1684 892789
. Yanhui Hu is a principal quality-by-design engineer in the quality assurance division at Abbott Laboratories.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here